Real-world Study of Two Cancer Drugs for Chronic Lymphocytic Leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)—a related blood cancer—and need treatment
- Your doctor must have already decided to treat you with ibrutinib plus venetoclax *before* this study was offered to you
- You have never received treatment for CLL or SLL before
- You are able to read and understand the study materials and answer survey questions in your local language
- You are not currently in another clinical trial testing a new drug or device, and have not been in one in the past 30 days
- You don't have any medical conditions that would prevent you from safely taking ibrutinib or venetoclax
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
This study looks at the long-term effects of taking ibrutinib and venetoclax together for chronic lymphocytic leukemia (CLL). It aims to see how well this treatment works over time and how it affects patients.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
This study tests a combination of two oral medications, venetoclax and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if this combination is safe and effective, either as a first treatment or after a previous treatment.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Hear when a new Leukemia, Lymphocytic, Chronic, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.